title: Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.
abstract: BACKGROUND
  Secondary bacterial infections following influenza represent a major cause of mortality in the human population, which, in turn, has led to a call for stockpiling of bacterial vaccines for pandemic preparedness.
  
  
  METHODS
  To investigate the efficacy of bacterial vaccination for protection against secondary pneumococcal infection, mice were immunized with pneumococcal capsular polysaccharide conjugate vaccine, and then sequentially coinfected 5 weeks later with PR8 influenza virus and A66.1 Streptococcus pneumoniae.
  
  
  RESULTS
  In the absence of influenza virus exposure, vaccination with polysaccharide conjugate vaccine was highly effective, as indicated by 100% survival from lethal pneumococcal pneumonia and 10 000-fold greater efficiency in clearance of bacteria from the lung compared to unvaccinated mice. Enhanced clearance after vaccination was dependent upon Fc receptor (FcR) expression. However, following influenza, <40% of vaccinated mice survived bacterial coinfection and FcR-dependent clearance of antibody-opsonized bacteria reduced bacterial levels in the lungs only 5-10 fold. No differences in lung myeloid cell numbers or in FcR cell surface expression were observed following influenza.
  
  
  CONCLUSIONS
  The results show that induction of antibacterial humoral immunity is only partially effective in protection against secondary bacterial infections that occur following influenza, and suggest that additional therapeutic strategies to overcome defective antibacterial immunity should be explored.
authors: Center for Immunology and Microbial Disease, Albany Medical College, New York.
authors: Dennis W
authors: DW
authors: Metzger
authors: Center for Immunology and Microbial Disease, Albany Medical College, New York.
authors: Yoichi
authors: Y
authors: Furuya
authors: Center for Immunology and Microbial Disease, Albany Medical College, New York.
authors: Sharon L
authors: SL
authors: Salmon
authors: Center for Immunology and Microbial Disease, Albany Medical College, New York.
authors: Sean
authors: S
authors: Roberts
authors: Center for Immunology and Microbial Disease, Albany Medical College, New York.
authors: Keer
authors: K
authors: Sun
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D022423:Myeloid Cells / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000494:pharmacology*; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000517:prevention & control*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D016019:Survival Analysis
chemical_list: D015703:Antigens, CD; D022242:Pneumococcal Vaccines
keywords: adaptive immunity; coinfection; influenza virus; innate immunity; pneumococcus; pneumonia; vaccination
references: World Health Organ Tech Rep Ser. 2005;927:1-154
references: 16454167
references: PLoS Pathog. 2011 Feb;7(2):e1001304
references: 21383977
references: Science. 2007 Apr 6;316(5821):49-50
references: 17412937
references: J Exp Med. 2008 Feb 18;205(2):323-9
references: 18227219
references: Nat Med. 2008 May;14(5):558-64
references: 18438414
references: J Infect Dis. 2008 Oct 1;198(7):962-70
references: 18710327
references: Vaccine. 2008 Sep 12;26 Suppl 4:D59-66
references: 19230162
references: J Clin Invest. 2009 Jul;119(7):1910-20
references: 19487810
references: Am J Respir Crit Care Med. 2011 Sep 1;184(5):547-60
references: 21471090
references: J Infect Dis. 2011 Oct 1;204(7):1086-94
references: 21881124
references: J Clin Invest. 2011 Sep;121(9):3657-65
references: 21841308
references: J Immunol. 2012 Nov 15;189(10):4921-9
references: 23028058
references: J Infect Dis. 2013 Apr;207(7):1135-43
references: 23303809
references: J Immunol. 2013 Aug 1;191(3):1250-9
references: 23804714
references: J Immunol. 2013 Aug 15;191(4):1792-9
references: 23833238
references: J Infect Dis. 2013 Oct 15;208(8):1281-5
references: 23852122
references: MBio. 2014;5(1). pii: e01040-13. doi: 10.1128/mBio.01040-13
references: 24549845
references: J Immunol. 2014 Apr 1;192(7):3301-7
references: 24563256
references: Infect Immun. 2003 Aug;71(8):4780-8
references: 12874361
references: Expert Rev Vaccines. 2004 Feb;3(1):35-42
references: 14761242
references: J Exp Med. 2004 Jul 19;200(2):267-72
references: 15263032
references: Nat Med. 2004 Aug;10(8):811-3
references: 15247911
references: Br Med J. 1958 Nov 29;2(5108):1305-11
references: 13596593
references: Lancet. 1958 Nov 29;2(7057):1141-3
references: 13612141
references: MMWR Morb Mortal Wkly Rep. 2009 Oct 2;58(38):1071-4
references: 19798021
references: J Virol. 2010 Apr;84(8):4105-8
references: 20130054
references: J Immunol. 2011 Jan 15;186(2):987-93
references: 21160043
references: J Immunol. 2011 Feb 1;186(3):1666-74
references: 21178015
references: Clin Microbiol Rev. 2006 Jul;19(3):571-82
references: 16847087